ClinicalTrials.gg
CompletedNCT01128959Updated Jan 16, 2018Results posted

Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy

A Phase 3 interventional study of Intravenous Carbamazepine (IV CBZ) in Epilepsy, sponsored by Lundbeck LLC. Completed at 29 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-16.

Sponsored by Lundbeck LLC (part of H. Lundbeck A/S) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
108
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing carbamazepine in Epilepsy — none open to participants now, none under way, none of them phase 3. Carbamazepine · Epilepsy.

Enrollment
4th of 10
108 · median 99
Started
2010
the only one that year
Phase 3
4 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
2 of 10
Lundbeck LLC

Among the 10 studies testing carbamazepine in Epilepsy, this one is the 4th largest by enrollment, is the only one that started in 2010, is one of 4 in phase 3, and was the 5th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

None of the 10 studies testing carbamazepine in Epilepsy is open now. The open studies under Epilepsy, anywhere →

About carbamazepine

Carbamazepine: first FDA approval 1968 (TEGRETOL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing carbamazepine in Epilepsy as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability of intravenous (IV) carbamazepine (CBZ) administered as multiple 15 minute infusions and a single 5 minute infusion to adult patients with epilepsy on stable higher doses of oral CBZ.

Read the detailed description

This was a phase III, multicenter, open-label study designed to assess the safety and tolerability of intravenously administered CBZ in adult patients with epilepsy. This study included a 28 day Lead-in Period, a Confinement Period (up to 7 days and 6 nights) and a 28 day Follow-up Period.

Patients began confinement on Day -1 of the trial, continuing to take their oral CBZ as prescribed by the investigator. On the morning of Day 0, Day 4, and Day 17, patients began the 24hr urine collection for evaluation of urinary biomarkers. All patients temporarily discontinued their prescribed oral CBZ and begin IV CBZ administration on the morning of Day 1, continuing administrations every 6 hours (Q6h) through the morning of Day 4.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Epilepsy
  • Intravenous Carbamazepine
  • Oral Carbamazepine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient or legal representative must be able to read, understand, sign and date the IRB approved Form and HIPAA Authorization prior to study participation.
  2. The patient is a man or a non-pregnant woman who is at least 18 years of age.
  3. If a woman:

    • Patient is either not of , defined as for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomay or hysterectomy), or if childbearing potential, must comply with a method of acceptable to the investigator during the study, for at least 28 days prior to Day 1 and for 28 days following completion of the study.
    • Patient is not breastfeeding.
    • Patient of childbearing potential must have a negative serum pregnancy test at Day -28 and a negative urine pregnancy test or serum pregnancy test at Day -1.
  4. The patient is diagnosed with any of the approved epilepsy indications for CBZ:

    • Partial seizures with complex symptomatology (psychomotor, temporal lobe)
    • Generalised tonic clonic seizures (GTCS) (grand mal): myoclonic, clonic, tonic, tonic-clonic, atonic
    • Mixed seizure patterns that include the above, or other partial or generalised seizures (except absence seizures - please see exclusion point number 12)
  5. The patient is receiving a stable dose of oral CBZ (tablet or capsule formulation) of 1200 mg/day to 2000 mg/day, for a minimum of 14 days prior to Day -28.
  6. The patient is receiving a constant dose of all other concomitant medications used for chronic conditions, (including OTC medications and herbal supplements) for a minimum of 28 days prior to Day 1.
  7. The patient is not expected to have any change in his/her baseline AED treatment during the treatment period.
  8. The patient is able to comply with maintaining an accurate Seizure and antiepileptic drug diary.
  9. The patient is able to comply with all study procedures including complying with protocol determined dosing intervals, confinement at the investigative site for up to 6 nights and 7 days, and agrees to participate in the entire study.

Exclusion criteria

Exclusion Criteria:

  1. The patient has a known to CBZ, Captisol, or to any of the tricyclic compounds, such as amitriptyline, trimipramine, imipramine; oxacarbazepine, phenytoin, or their analogues or metabolites.
  2. The patient has a history of previous bone marrow depression.
  3. The patient has a history of intolerance to IV administration of medication.
  4. The patient is pregnant or lactating.
  5. The patient is being treated with a monoamine oxidase (MAO) inhibitor.
  6. The patient is using oral, intramuscular, or any other hormone delivery method as their primary form of .
  7. The patient has an with interval by Fridericia's correction formula (QTcF) greater than 450 msec at Screening or Day -1.
  8. The patient has a screening , AST or >=3 times the .
  9. The patient has an estimated ClCR (based of ) of \<50 ml/min.
  10. The patient has had a illness/infection or has had any surgical procedure within 30 days prior to Screening.
  11. The patient has a significant history of cardiac, renal, neurologic (other than epilepsy), psychiatric, oncologic, endocrinologic, metabolic, or hepatic disease, which would adversely affect their participation in this study.
  12. The patient is receiving oral CBZ for absence seizures.
  13. The patient has had an episode of status epilepticus within 4 weeks of Screening.
  14. The patient has a history of severe or serious adverse reactions to CBZ (for example, aplastic anemia, agranulocytosis, SJS.
  15. The patient has taken or used any drug or device in the 30 days prior to Screening.
  16. The patient has previously been administered IV CBZ in a previous clinical trial (for example OV-1015).
  17. The patient has a urine toxicology screen positive for phencyclidine, benzodiazepines (unless due to the patient's concomitant AEDs), cannabinoids, cocaine, amphetamines, opiates, barbiturates (unless due to the patient's concomitant AEDs), or alcohol at Screening or Day -1.
  18. The patient has had a diagnosis of drug or alcohol abuse within the past year prior to Screening.
  19. The patient has had significant blood loss (>500 mL) or donation within 14 days of Screening.
  20. The patient has a history of poor oral CBZ compliance.
  21. The patient is participating in a weight loss or nicotine cessation program.
  22. The patient has a history of increased intraocular pressure or is on medication for glaucoma.
  23. The patient is considered by the investigator to be an unsuitable candidate for the study, which may include an increase in the frequency, severity and duration of seizures during the Pre-Treatment Period (Days -28-0).
  24. The patient has previously participated in this study.
  25. The patient is a member of the site personnel or their immediate families.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    Intravenous Carbamazepine (IV CBZ)

    Drug: Intravenous Carbamazepine (IV CBZ)

Interventions

  • 10 mg/mL of IV CBZ dissolved in 250 mg/mL of Captisol® (sulfobutylether-beta-cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by IV infusion every 6 hours.

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Time frame: Baseline to after last iv dose on day 4

07

Results

Posted Dec 5, 2016

Participant flow

The patients were recruited through physician referrals and/or recruitment methods at hospitals and clinics. Advertisements were used by 5 sites.

Lead in Period
Participant flow — Lead in Period
MilestoneIntravenous Carbamazepine (IV CBZ)
Started108
Completed105
Not completed3
Withdrew: Adverse event3
Treatment Period
Participant flow — Treatment Period
MilestoneIntravenous Carbamazepine (IV CBZ)
Started105
Completed101
Not completed4
Withdrew: Adverse event3
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryAdverse Events
Time frame:
Baseline to after last iv dose on day 4
Reported as:
Number · Number of adverse events
Adverse Events
Number of adverse eventsIntravenous Carbamazepine (IV CBZ) 15 Minutes InfusionIntravenous Carbamazepine (IV CBZ) 5 Minutes Infusion
Adverse Events12626

Adverse events

Collected over Baseline to to after last iv dose on day 4. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intravenous Carbamazepine (IV CBZ) 15 Minutes Infusion—2/105 (1.9%)29/105 (27.6%)
Intravenous Carbamazepine (IV CBZ) 5 Minutes Infusion—0/101 (0%)11/101 (10.9%)
Most frequent serious events
Most frequent serious events
EventIntravenous Carbamazepine (IV CBZ) 15 Minutes InfusionIntravenous Carbamazepine (IV CBZ) 5 Minutes Infusion
Cerebral HaemorrhageNervous system disorders1/1050/101
ConvulsionNervous system disorders1/1050/101
Most frequent other events
Most frequent other events
EventIntravenous Carbamazepine (IV CBZ) 15 Minutes InfusionIntravenous Carbamazepine (IV CBZ) 5 Minutes Infusion
DizzinessNervous system disorders20/10511/101
HeadacheNervous system disorders9/1050/101
SomnolenceNervous system disorders7/1051/101

Baseline characteristics

Age, Continuous
Age, Continuous(years)Intravenous Carbamazepine (IV CBZ)
Mean40.7 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Intravenous Carbamazepine (IV CBZ)
Female52
Male53
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Intravenous Carbamazepine (IV CBZ)
American Indian or Alaska Native1
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American22
White72
More than one race0
Unknown or Not Reported8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Intravenous Carbamazepine (IV CBZ)
Hispanic or Latino19
Not Hispanic or Latino86
Unknown or Not Reported0
08

Study locations

29 sites
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • Clinical Trials Incorporated
    Little Rock, Arkansas 72205, United States
  • Collaborative Neuroscience Network, Inc.
    Torrance, California 90502, United States
  • Denver Health and Hospital Authority
    Denver, Colorado 80204, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • University of Illinois at Chicago
    Chicago, Illinois 60612, United States
  • Southern illinois University School of Medicine
    Springfield, Illinois 62702, United States
  • Central DuPage Hospital
    Winfield, Illinois 60190, United States
  • Via Christi Epilepsy Center
    Wichita, Kansas 67214, United States
  • Leonard J. Chabert Medical Center
    Houma, Louisiana 70363, United States
  • Louisiana Research Associates
    New Orleans, Louisiana 70114, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70115, United States
  • Mid-Atlantic Epilepsy and Sleep Center
    Bethesda, Maryland 20815, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • University of Minnesota & Prism Research
    Saint Paul, Minnesota 55114, United States
  • The Comprehensive Epilepsy Care Center for Children and Adults
    Chesterfield, Missouri 63017, United States
  • Montefiore Medicical Center
    Bronx, New York 10467, United States
  • Langone Medical Center NYU Comprehensive Epilepsy Center
    New York, New York 10016, United States
  • Columbia University Medical Center: Dept of Neurology
    New York, New York 10032, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Temple University Health systems
    Philadelphia, Pennsylvania 19140, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Neurological Clinic of Texas, P.A.
    Dallas, Texas 75230, United States
  • Scott & White Memorial Hospital
    Temple, Texas 76508, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
  • VCU Medical Center
    Richmond, Virginia 23298-0599, United States
09

References and documents

Publications

  • Lee D, Kalu U, Halford JJ, Biton V, Cloyd J, Klein P, Bekersky I, Peng G, Dheerendra S, Tolbert D. Intravenous carbamazepine as short-term replacement therapy for oral carbamazepine in adults with epilepsy: Pooled tolerability results from two open-label trials. Epilepsia. 2015 Jun;56(6):906-14. doi: 10.1111/epi.12991. Epub 2015 Apr 25. PubMed 25912051 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 3 years 11 months after primary completion. A results delay was requested in Apr 2014.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2010
First posted
May 24, 2010
Start
Jun 2010
Primary completionActual
Jan 2013
CompletionActual
Jan 2013
Results delay requested
Apr 11, 2014
Results first posted
Dec 5, 2016
Last update
Jan 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01128959
Lead sponsor
Lundbeck LLC
Collaborators
Ligand Pharmaceuticals, ICON Clinical Research, Quintiles, Inc.
Responsible party
Sponsor
First posted
May 24, 2010
Start date
Jun 2010
Primary completion
Jan 2013
Completion
Jan 2013
Results posted
Dec 5, 2016
Last update
Jan 16, 2018

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carbamazepine

Start the discussion